独角兽企业作为世界级创业生态的标志，是一座城市经济发展的稀缺宝贵资源，已经成为衡量一个地区 创新能力、创业生态的重要观察指标。为何这么多独角兽都诞生在广东？ 近日，胡润研究院在广州发布《2025全球独角兽榜》，列出了全球成立于2000年之后、价值10亿美元以 上的非上市公司。数据显示，全球独角兽企业数量达到1523家，比去年增加了70家。其中，美国以758 家独角兽企业领先，中国以343家独角兽企业位居第二。 本次榜单可见，全国343家独角兽企业中，有1/5都是"粤字号"。广东独角兽"军团"有多能打？本期信心 有数一起看！ 广东独角兽数量超印度 70家=德+法+越三国总和 单看数量，广东独角兽"军团"就已领先全国。全国每5家独角兽企业，就有1家在广东。《2025全球独角 兽榜》显示，广东共有70家独角兽上榜。其中，深圳有37家，居全国第3、全球城市第6位，是国内独角 兽企业增长最快城市；广州有24家，居全国第4、全球城市第11，希音以3650亿元人民币的估值持续位 居全球十强。 放眼全球，广东独角兽"军团"表现也格外突出。从数量上看，广东独角兽企业数量超越全球第三的印度 （64家），相当于德国（36家）、法国 ...

Core Points - The company announced a cash dividend distribution of 0.8 RMB per share, totaling 101,666,244 RMB based on a total share capital of 127,082,805 shares [1] - The dividend distribution plan was approved at the annual general meeting held on May 22, 2025 [1] - The cash dividend will be distributed to shareholders registered by the end of the trading day on the record date [1] Dividend Distribution Details - The cash dividend of 0.8 RMB per share is inclusive of tax [1] - The distribution will be managed by China Securities Depository and Clearing Corporation Limited, Shanghai Branch [1] - Shareholders who have not completed designated transactions will have their dividends held by the clearing company until the transactions are completed [1] Tax Implications - For individual shareholders holding unrestricted shares for over one year, the dividend income is exempt from individual income tax [3] - For shares held for less than one year, the tax treatment varies: 20% tax for holdings of one month or less, and 10% tax for holdings between one month and one year [3] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, resulting in a net dividend of 0.72 RMB per share [5] - Hong Kong investors will also receive a net dividend of 0.72 RMB per share after a 10% tax withholding [5]

Core Viewpoint - The company reported a 21.78% year-on-year revenue growth for 2024, attributed to increased procurement demand from major clients, new product development, sales channel expansion, and the acquisition of a new subsidiary, Shanenkang [1] Group 1: Financial Performance - The company recorded a goodwill impairment provision of 39.62 million yuan due to the underperformance of Shanenkang, which failed to meet its profit commitments post-acquisition [2] - The acquisition of Shanenkang was completed on April 7, 2024, resulting in a goodwill of 91.01 million yuan, with a significant asset appreciation rate of 656.94% [2][3] - Shanenkang's actual net profit for 2024 was -0.9026 million yuan, leading to a failure in achieving the promised cumulative net profit of 60 million yuan over three years [2][4] Group 2: Goodwill Impairment Testing - The company conducted a goodwill impairment test, determining that the recoverable amount of Shanenkang's asset group was 198 million yuan, indicating a reduction of approximately 69.33 million yuan from the book value [4] - The management based the impairment test on historical gross margin data and market forecasts, adjusting the focus towards high-margin products in the AKK bacteria market [3][4] Group 3: Long-term Investment in Weimeizi - The company reported a long-term equity investment in Weimeizi with a balance of 711 million yuan, resulting in an investment loss of 8.71 million yuan for the reporting period [5] - Weimeizi faced significant challenges due to a decline in offline sales and ongoing shareholder disputes, leading to a substantial increase in impairment provisions from 50.32 million yuan to 138 million yuan [5][6] - The company noted that Weimeizi's marketing expenses increased significantly in 2024 as part of its transformation strategy, but this did not translate into higher revenue [6][7]

Core Insights - The article highlights the successful integration of education and employment at Anhui Agricultural University, focusing on the cultivation of practical skills and job readiness among graduates [1][2][3] Group 1: Employment and Education Integration - Anhui Agricultural University has signed employment agreements with multiple graduates, emphasizing their strong foundational skills and practical abilities [1] - The university has trained over 26,000 graduates in the past three years, with 68.6% choosing to work in grassroots positions and 74.37% remaining in Anhui [1] - The institution has adjusted its curriculum to meet modern agricultural demands, introducing eight new majors, including biological breeding and smart agriculture [2] Group 2: Practical Training and Skill Development - The university has established a collaborative ecosystem with companies like Qianying High-Tech, allowing students to gain hands-on experience from learning to employment [2] - Students participate in comprehensive training programs, such as the "Fengsui Action - Agricultural Pioneer Training Camp," which covers all aspects of agricultural production [2] - The university has conducted extensive surveys to understand employer needs, leading to tailored employment guidance and skill enhancement programs [3] Group 3: Innovative Programs and Collaborations - The "Wankeng Innovation Class" was launched in collaboration with Anhui Agricultural Group, focusing on practical training and academic integration [5] - The university has developed various innovative classes and partnerships with local enterprises to foster modern agricultural talent [6] - A total of 352 internal and 162 external innovation and entrepreneurship mentors have been appointed, establishing strategic partnerships with 283 leading companies [6]

Core Viewpoint - Nanwei Technology (688690) is experiencing growth driven by the booming GLP-1 peptide drug market, leading to increased investment in new drug research and production capacity by domestic and international pharmaceutical companies [2][3]. Group 1: Business Performance - The company's main revenue for Q1 2025 was 189 million yuan, a year-on-year increase of 22.39%, with a net profit attributable to shareholders of 29.22 million yuan, up 72.98% year-on-year [7]. - The gross profit margin for the chromatography filler business is high, accounting for approximately 60% of the company's revenue, which has improved overall profitability [4]. Group 2: Market Strategy - The company is focusing on the antibody new drug projects as a key area for replacing imported products, enhancing competitiveness through continuous R&D investment and product innovation [3]. - To address domestic competition, the company is building a comprehensive chromatography technology platform, providing integrated solutions to avoid price wars in single product categories [6]. Group 3: Mergers and Acquisitions - The acquisition of two instrument companies enhances the company's product line from chromatography fillers to protein purification equipment, improving business and product layout and achieving synergy in customer expansion and market sales [5]. Group 4: Future Outlook - The company is accelerating its overseas market layout and enhancing its overseas sales capabilities to increase application opportunities for its filler products among international clients [3][6].

2、藥明生物 (02269.HK)：沖高破頂，能上30嗎？窩輪市場，投資者表示在27元有壓力，反手做put。 Simon:比較有趣的情況，正股升，窩輪市場的投資者則反手做空。暫時技術信號為"買入"，15個買入信號，沒有賣出信號。為什麼未有到"強力買入"呢？因 為還有9個中立信號。如果再上的話，首先看兩個阻力位28.5元和29.5元。低於30元水位。留意下周走勢的變化。 1、恆指：看多投資者表示在24000點入牛，如果跌24000就止損。看淡投資者則認為放量了，下周低開至24000，部署的熊證，收回價24888。也 有投資者持有熊證，收回價24600，止損離場，空倉過夜。 Simon：很多時候投資者對於市場的看法都是偏短線，不管窩輪還是牛熊證，投資部署都是偏短線，比如炒日內、或揸1-2日。所以我們用技術分析作為參 考，讓大家知道當前市況，作為短線走勢會如何？希望可以提供更多數據給短線交易的投資者，瞭解到目前市場的變化如何。比如恆指，最新的信號總結 為"買入"，看多信號為主。第一個阻力位在24600點附近，突破則上試25000點。投資者部署收回價在24888點左右的熊證，其實比較安全的，在兩個阻力位 之間。另外我 ...

850%股息率，疫情红利耗尽后的"清仓式"分红 7月9日，科兴生物召开特别股东大会。股东投票通过了赛富基金（SAIF）提出的两项提案：罢免现任董事会成员，并选举SAIF提名的十位资深董事候选人 进入董事会，尹卫东阵营占据绝大多数席位。 7月9日，停牌逾六年的科兴生物（NASDAQ：SVA）上演了一场控制权争夺的终极对决。股东投票通过赛富基金提案，罢免由李嘉强主导的现任董事会， 并选举以创始人尹卫东阵营为核心的新十人董事会。然而会议刚落幕，李嘉强即向媒体回应该决议"不合法"，双方围绕董事会合法性的死结仍未解开。 这场冲突的导火索源于科兴生物于7月初抛出的"清仓式分红"计划——总额最高75亿美元（约538亿元人民币），每股分红上限达124美元，相当于停牌前股 价6.47美元的19倍。首期每股55美元的股息已于股东大会前支付，股息率高达850%，逾33亿美元现金涌入股东账户。 如此天价派现，实为新冠疫情期间天量利润的集中释放：2021年其疫苗收入飙升至193.75亿美元，净利润暴增7572%至84.67亿美元，但2023年迅速跌入亏 损，非新冠业务收入始终未突破2亿美元/年。分红后，公司现金储备消耗超七成，仅剩约2 ...

新京报贝壳财经讯（记者胡萌）7月11日，2025贝壳财经年会"中国经济：开放与韧性 共生长"在北京召 开。锦波生物董事、副总经理兼董事会秘书唐梦华在出席圆桌论坛"科创与金融共振，北交所助力'新 质'先锋"中透露了与养生堂战略合作的更多细节。 值得注意的是，2025年，锦波生物股价、市值双双晋升为北交所第一名。回顾在北交所的上市经历，唐 梦华坦言，"在我们发展的当期，北交所是最适合我们的交易场所，未来回溯也是这个选择。"彼时，锦 波生物的营收超过1亿元，净利润在3000万-4000万元之间。 唐梦华表示，"北交所的机制设置更符合公司发展需求。一方面，北交所的发行规模没有沪深两市那么 高，我们可以根据实际需要进行融资，发行比例更加灵活，也为未来的再融资奠定了基础，同时北交所 上市提升了公司的市场形象和品牌公信力，也推动了业务发展。" 编辑 杨娟娟 校对 卢茜 今年6月底，锦波生物披露，将向养生堂有限公司（以下简称"养生堂"）特定对象发行股票并签署股份 认购协议，公司控股股东和实控人杨霞还将向久视管理咨询（杭州）合伙企业（有限合伙）（以下简称 杭州久视）转让股份，两项交易（融资额+转让款）合计为34.03亿元。 据 ...

Core Viewpoint - The Shenzhen Stock Exchange announced revisions to the ChiNext Composite Index, introducing monthly removal mechanisms for risk-warning stocks and ESG negative-rated stocks, effective from July 25, 2025 [1][4]. Group 1: Index Revisions - The ChiNext Composite Index will implement a monthly removal mechanism for stocks under risk warning (ST or *ST) and will exclude stocks rated C or below in ESG assessments [4]. - The revisions aim to enhance the index's stability and promote responsible investment by filtering out high-risk and low-governance companies [4][7]. Group 2: Fund Company Responses - Following the announcement, seven fund companies quickly submitted applications for ChiNext-related ETFs, including Penghua Fund, Yinhua Fund, and Bosera Fund for standard ETFs, and Jianxin Fund, Huabao Fund, and others for enhanced ETFs [1][3]. - Fund managers believe that the revised index will attract long-term capital inflows and provide a more transparent investment tool for innovative sectors [4][6]. Group 3: Index Characteristics and Market Impact - As of July 11, 2025, the ChiNext Composite Index will consist of 1,316 stocks, covering 95% of listed companies on the ChiNext, with a total market capitalization coverage of 98% [5]. - The index is seen as a crucial investment vehicle for capturing growth in sectors like renewable energy, biomedicine, and electronic information technology, reflecting the overall market trends [5][6]. - The ChiNext Composite Index has outperformed the ChiNext Index over the past decade, with an annualized return approximately 2% higher [6]. Group 4: Future Developments - The Shenzhen Stock Exchange plans to continue enhancing the "Chuang Series" indices and related products, focusing on serving national strategic priorities and improving the quality of investment options available [9].

Group 1 - The average stock price of the Sci-Tech Innovation Board is 30.90 yuan, with 41 stocks priced over 100 yuan, and the highest priced stock is Cambrian Technology at 553.98 yuan, which increased by 5.82% [1][2] - Among the stocks priced over 100 yuan, 402 stocks rose today while 175 stocks fell, with an average increase of 1.81% for the hundred-yuan stocks [1][2] - The average premium of the hundred-yuan stocks relative to their issue price is 328.22%, with notable premiums from companies like Anji Technology (1073.59%), Baile Tianheng (1038.66%), and Hotgen Biotech (897.09%) [1][2] Group 2 - The net inflow of main funds for hundred-yuan stocks today totaled 834 million yuan, with significant inflows into Cambrian Technology (436.09 million yuan), Haiguang Information (162.74 million yuan), and Zhongwei Company (81.32 million yuan) [2] - The total margin financing balance for hundred-yuan stocks is 26.065 billion yuan, with leading balances from Haiguang Information (3.579 billion yuan), Cambrian Technology (3.497 billion yuan), and Zhongwei Company (2.706 billion yuan) [2] - The stocks with the highest trading volume and price changes include Cambrian Technology, Huatai Medical, and Maolai Optics, with respective closing prices of 553.98 yuan, 295.00 yuan, and 281.59 yuan [2][3]